Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anesiva Zingo gets fast-acting approval

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA's Aug. 16 approval of the fast-acting topical local analgesic comes five weeks ahead of the NDA's Sept. 24 user fee goal. The needle-free Zingo system delivers 0.5 mg lidocaine powder into the epidermis of the skin, providing local analgesia one to three minutes after administration. Commonly used local anesthetics take 20 minutes or longer to act, Anesiva notes. Zingo is approved to reduce pain associated with venous access procedures, such as IV insertions or blood draws, in children ages 3 to 18. The company plans to file an sNDA broadening the label to include adults by the end of the year...

You may also be interested in...



'Touchless Plants' To Virtually Trained Workforces - Indian Cos Share Digitalization Tips

Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.

More IVD Mergers: Agilent Buys Resolution, Hologic Acquires Diagenode

Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.

Merck & Co. Will Manufacture J&J Vaccine, Other COVID-19 Medicines Under BARDA Deal

Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel